Is Johnson & Johnson a Buy After Its Latest Earnings Report?

Johnson & Johnson (JNJ) fell 3% after reporting Q2 earnings that beat analyst estimates but revealed cracks in its medical device business. The company posted a beat on the top and bottom lines, yet investors focused on a 2% decline in Abiomed heart pump sales, potentially tied to a negative UK study.

The pharmaceutical segment showed strength, with Darzalex and Tremfya driving growth, though management acknowledged the pace lagged behind competitors. JNJ raised its 2026 guidance, signaling confidence in the longer-term trajectory, but the near-term concerns around Abiomed overshadowed the positive developments.

The Abiomed weakness is particularly notable given the company acquired the heart pump maker in a multi-billion dollar deal. The 2% sales drop, if linked to the UK study findings, could indicate headwinds for the broader medical device portfolio and raises questions about JNJ's ability to maintain growth across its diversified segments.